Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

June 29, 2022

Femoral Popliteal DVT

Presentation LINC 2019

Femoral Popliteal DVT

Presenter: Robert Lookstein

January 25, 2019

Varicose Veins Linked to Increased Risk of DVT

News Daily News

Varicose Veins Linked to Increased Risk of DVT

February 28, 2018

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

News Industry News

Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

November 30, 2015

Rationale and Novel Treatment Techniques for Treatment of Femoropopliteal Chronic DVT

Presentation VEINS 2014

Rationale and Novel Treatment Techniques for Treatment of Femoropopliteal Chronic DVT

Presenter: Stephen T. Kee

October 11, 2014

Treatment of Femoropopliteal DVT: Anticoagulation (and Compression) Is Enough

Presentation VEINS 2014

Treatment of Femoropopliteal DVT: Anticoagulation (and Compression) Is Enough

Presenter: Suresh Vedantham

October 10, 2014

DEBATE: Treatment of Femoropopliteal DVT - No, We Must Consider Aggressive Measures

Presentation VEINS 2014

DEBATE: Treatment of Femoropopliteal DVT - No, We Must Consider Aggressive Measures

Presenter: Mark J. Garcia

October 10, 2014

Iliofemoral DVT In Pregnacy: Delivery Results NOT the Baby

Presentation VEINS 2014

Iliofemoral DVT In Pregnacy: Delivery Results NOT the Baby

Presenter: Mark Goodwin

October 10, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.